Mixed-dose radiation with chemo-immunotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new mix of high and low dose radiation along with chemotherapy and immunotherapy for people with locally advanced non-small cell lung cancer. It aims to see if this combination can improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that has not spread to other parts of the body or has only limited spread that can be safely treated with radiation.
- You are older than 18 years.
- Your cancer does not have certain genetic mutations (EGFR, ALK, ROS1, RET, MET, HER2, BRAF, KRAS G12C).
- You have at least one lung tumor larger than 2 centimeters and lymph nodes in the chest that are involved.
- You are in good overall health (able to do daily activities without help) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This trial studies whether pembrolizumab combined with standard chemo can treat locally advanced, unresectable stage III lung cancer without giving radiation first. It is intended for people whose tumor has high PD-L1 (a marker linked to how well immunotherapy may work).
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.